In 2011, Dr. Vrabec was excited to be chosen as the first surgeon in the state to participate in an FDA Study for Corneal Collagen Crosslinking (CXL). CXL is a developing keratoconus treatment, in which drops of riboflavin are applied to the cornea, which is then activated by an ultraviolet light. The goal of this is to strengthen the bonds of the cornea, thereby slowing the progression of keratoconus. Today, Dr. Vrabec performs this treatment on patients on a regular basis.
For more information about this exciting new treatment, please visit the following websites:
Call (800) 344-4443 for more information or to schedule an appointment.